The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.
Other Programs Supported by The Life Raft Group:
PATIENT
Leverage patient perspective to drive innovative solutions in cancer research.
POWERED
Educate and empower patients to take a larger role in their care.
SCIENCE
Accelerate research outcomes through collaborative efforts.
FOR LIFE
Increase access to effective treatments worldwide.
Real World Evidence In Action
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to GIST research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Did you know that GIST is actually a family of cancers? Learn more about the science of GIST.
Update your Patient Registry Info.
Join The Life Raft Group.
Current GIST Clinical Trials.
Search the GIST Specialist Database.
Dr. Monica Anderson
Diagnosed in 2012 with Adult GIST.
Bella Rocco
Diagnosed in 2009 with Pediatric
(SDH-deficient) GIST.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
News
Indian Generic Drug Quality Questioned by FDA and U.S. Doctors
Indian generic drug quality has been questioned recently by a number of U.S. doctors. The concern stems from FDA recalls and import bans.
Trial Finds that Adjuvant Imatinib Impacts Recurrence-Free Survival
A recent clinical trial found that 1 year of adjuvant imatinib was able to increase recurrence-free survival. Keep reading to learn more.
Imatinib Rechallenge Impacts GIST Survival Rate
A recent nonrandomized study has shown that imatinib rechallenge impacted the survival rate for patients with advanced or metastatic gastrointestinal stromal tumor (GIST).
The GIST Cancer Journal Arrives
The Life Raft Group is pleased to announce the release of the first issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to GIST.
Drugs being Reconsidered to help Fight GIST
The LRG helped fund research by the University of Pittsburgh Cancer Institute (UPCI) to screen a library of FDA-approved anticancer drugs that previously wouldn’t have [...]
New Treatments on the Horizon for GIST?
There are two new treatments that may have an impact on fighting GIST – immunotherapy and MRI-guided radiation. The LRG is continually looking into new treatments for GIST.
Jim Mills shares his journey with GIST
In 2006, GIST patient Jim Mills was generous enough to share his GIST journey to the Life Raft Group.
Tamara Taggart: Cancer cover girl
Tamara Taggart is the cover girl for a British Columbia (BC) magazine that debuted last month.
Keep up with the latest news, events, and opportunities to help.
To contact The Life Raft Group, please call 973-837-9092
PARTNERS & AFFILIATIONS
